- RecruitingPHASE3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
This study is for children and teenagers aged 6-17 who are overweight or have obesity. It's testing a new medication called Orforglipron to see if it's safe and helps with weight management, compared to a dummy medicine. It aims to find better ways to help young people manage their weight.
For: Obesity · OverweightUnited States · Brazil · Israel - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
For: Atherosclerosis Cardiovascular Disease · Chronic Kidney DiseaseArgentina · Australia · Austria - RecruitingPHASE3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
This study is testing a new medicine, Orforglipron, for people with a common blood vessel problem called Peripheral Arterial Disease (PAD) that causes leg pain when walking. It aims to see if the medicine is safe and helps improve symptoms.
For: Peripheral Arterial DiseaseUnited States · Argentina · Australia - Not yet recruitingPHASE3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
This study is looking at a new medicine called orforglipron for young people aged 10-17 with type 2 diabetes. It compares it with an existing medicine, dulaglutide, to see how well it works and if it's safe. The study lasts about 61 weeks.
For: Diabetes Mellitus, Type 2United States · Belgium · Brazil - RecruitingPHASE3
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
This study is looking at a new once-a-day tablet, orforglipron, for teenagers (12-17 years old) with obesity or who are overweight with other health issues. It will check if the medicine helps with weight and if it's safe to use.
For: Obesity · OverweightUnited States · Israel · Italy - Active not recruitingPHASE3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
This study is testing a new medicine, orforglipron, to see if it can help people manage high blood pressure when they also have obesity or are overweight. Researchers want to find out if it is safe and works well. Some people will get the medicine, and others will get a dummy pill.
For: HypertensionUnited States · Argentina · China - Active not recruitingPHASE3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
This study is looking at a new medicine called orforglipron for people with high blood pressure who are also overweight or living with obesity. It aims to see if the medicine can help reduce blood pressure and if it's safe to use. Half the participants will get the medicine, and the other half will get a dummy pill.
For: HypertensionUnited States · Argentina · China - Active not recruitingPHASE3
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
This study looks into a new medication called orforglipron for people with sleep apnoea and who are overweight or obese. It checks how well it works and if it's safe, especially for those who can't or don't want to use CPAP, or for those already using continuous positive airway pressure (CPAP).
For: OSA · Overweight or ObesityUnited States · Argentina · Brazil - Active not recruitingPHASE3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
This study is looking at a new medicine called orforglipron for people with obesity or who are overweight and have type 2 diabetes. It wants to see how well it helps control blood sugar compared to a dummy medicine, called a placebo.
For: Obesity · Overweight · Type 2 DiabetesUnited States · Argentina · China - Active not recruitingPHASE3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
This study is looking at a new medicine called orforglipron to help people who are overweight or have obesity lose weight. It's for adults with at least one other health condition linked to their weight, but not diabetes. It will last about 18 months.
For: Obesity · OverweightUnited States · Argentina · China